A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium

Pediatric Blood and Cancer

Volumn 60, Issue 11, 2013, Pages 1868-1874

  Zorzi, Alexandra P ^a   Bernstein, Mark ^b   Samson, Yvan ^c   Wall, Donna A ^d   Desai, Sunil ^e   Nicksy, Darcy ^f   Wainman, Nancy ^g   Eisenhauer, Elizabeth ^g   Baruchel, Sylvain ^f  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b IWK HEALTH CENTRE   (Canada)

^c Division of Hematology/Oncology   (Canada)

^d Cancer Care Manitoba   (Canada)

^e STOLLERY CHILDREN S HOSPITAL   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g Queen's Cancer Research Institute   (Canada)

Author keywords

Histone deacetylase inhibitor; Pediatric cancer; Phase I trial; Pracinostat; Solid tumor

Indexed keywords

PRACINOSTAT; SB 939; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CENTRAL VENOUS CATHETER; CHILD; CHILDHOOD CANCER; CHILL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG HALF LIFE; DYSPNEA; EPISTAXIS; EWING SARCOMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEART FUNCTION; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MUCOSA INFLAMMATION; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; NONCARDIAC CHEST PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; QT PROLONGATION; RHABDOMYOSARCOMA; SCHOOL CHILD; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; VOMITING;

HISTONE DEACETYLASE INHIBITOR; PEDIATRIC CANCER; PHASE I TRIAL; PRACINOSTAT; SOLID TUMOR;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; INFANT; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS;

EID: 84883806177     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24694     Document Type: Article

References (21)

1. Piekarz RL, Bates SE. Epigenetic modifiers: Basic understanding and clinical development. Clin Cancer Res 2009; 15:3918-3926.
2. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: Mechanisms and potential clinical implications. Clin Cancer Res 2009; 15:3947-3957.
3. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007; 76:75-100.
4. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007; 26:5541-5552.
5. Glick RD, Swendeman SL, Coffey DC, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 1999; 59:4392-4399.
6. Jaboin J, Wild J, Hamidi H, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002; 62:6108-6115.
7. Novotny-Diermayr V, Sangthongpitag K, Hu CY, et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 2010; 9:642-652.
8. Novotny-Diermayr V, Sausgruber N, Loh YK, et al. Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue. Mol Cancer Ther 2011; 10:1207-1217.
9. Yong WP, Goh BC, Soo RA, et al. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann Oncol 2011; 22:2516-2522.
10. Razak AR, Hotte SJ, Siu LL, et al. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer 2011; 104:756-762.
11. Lin HY, Chen CS, Lin SP, et al. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006; 26:397-413.
12. Fouladi M, Furman WL, Chin T, et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: A Children's Oncology Group report. J Clin Oncol 2006; 24:3678-3685.
13. Fouladi M, Park JR, Stewart CF, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: A Children's Oncology Group phase I consortium report. J Clin Oncol 2010; 28:3623-3629.
14. Isotalo PA, Greenway DC, Donnelly JG. Metastatic alveolar rhabdomyosarcoma with increased serum creatine kinase MB and cardiac troponin T and normal cardiac troponin I. Clin Chem 1999; 45:1576-1578.
15. Kim MS, Blake M, Baek JH, et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63:7291-7300.
16. Coffey DC, Kutko MC, Glick RD, et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 2000; 35:577-581.
17. Coffey DC, Kutko MC, Glick RD, et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 2001; 61:3591-3594.
18. Ferrara FF, Fazi F, Bianchini A, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61:2-7.
19. Kawano T, Horiguchi-Yamada J, Iwase S, et al. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. Anticancer Res 2004; 24:2705-2712.
20. Bali P, George P, Cohen P, et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 2004; 10:4991-4997.
21. Qian DZ, Wang X, Kachhap SK, et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2004; 64:6626-6634.